And sometimes you can find stocks that are especially great bargains. Three Motley Fool contributors believe they've done just that. Here's ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate ... Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.

Biohaven, Roche, Novartis, Pfizer, and Takeda. Boehringer said the GPR52 agonists have the potential to tackle the gamut of symptoms in schizophrenia, not only positive symptoms like delusions and ...

In March 2024, InvestingPro’s Fair Value model identified Biohaven Ltd. (NYSE:BHVN) as significantly overvalued at $56.37. One year later, this analysis has proven remarkably accurate ...

(Reuters) -U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna (NASDAQ:MRNA) Inc ...

The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

Pfizer sells entire Haleon stake for $3.24 billion Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer ...

Roku Inc is a pioneer in TV streaming, offering a platform that makes finding and watching TV shows, movies, news, and sports easier. With a focus on user experience, Roku sells streaming players ...

PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic ...